Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis

Prognostic markers are urgently needed to optimize the postoperative treatment strategies for gastrointestinal stromal tumors (GIST). GIST of the small intestine (I‐GIST) show more aggressive behavior than those of the stomach (S‐GIST), and the molecular background of the malignancy in I‐GIST may include potential prognostic biomarkers. We conducted integrated proteomic and transcriptomic analysis to identify genes showing differential expressions according to the tumor site. We generated protein expression profiles for four cases each of surgically resected I‐GIST and S‐GIST using label‐free proteomic analysis. For proteins showing differential expressions, global mRNA expression was compared between 9 I‐GIST and 23 S‐GIST. Among the 2555 genes analyzed, we found that promyelocytic leukemia (PML), a tumor suppressor gene, was significantly downregulated in I‐GIST at both the protein and mRNA levels (P < 0.01; fold difference ≥2.0). Immunohistochemistry of 254 additional cases from multiple clinical facilities showed that PML‐negative cases were significantly frequent in the I‐GIST group (P < 0.001). The 5‐year recurrence‐free survival rate was significantly lower in the PML‐negative than in the PML‐positive cases (60.1% vs 91.7%; P < 0.001). Multivariate analysis revealed that downregulation of PML was an independent unfavorable prognostic factor (hazard ratio = 2.739; P = 0.001). Our study indicated that prognostication based on PML expression may have potential for optimizing the treatment strategy for GIST patients. Further validation studies of PML for clinical application, and investigation for the mechanistic significance of PML to clarify the molecular backgrounds of malignancy in GIST are warranted.

[1]  H. Joensuu.  Adjuvant treatment of GIST: patient selection and treatment strategies , 2012, Nature Reviews Clinical Oncology.

[2]  C. Tzeng,et al.  Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. , 2004, Journal of biomedical science.

[3]  J. Fletcher,et al.  KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway , 2007, Oncogene.

[4]  Ailan Guo,et al.  The function of PML in p53-dependent apoptosis , 2000, Nature Cell Biology.

[5]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[6]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[7]  Pier Paolo Pandolfi,et al.  The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network , 2008, Nature.

[8]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[9]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[10]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[11]  Rachel M. Adams,et al.  Systematic comparison of label-free, metabolic labeling, and isobaric chemical labeling for quantitative proteomics on LTQ Orbitrap Velos. , 2012, Journal of proteome research.

[12]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[13]  J. Vermeesch,et al.  Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status , 2007, Genes, chromosomes & cancer.

[14]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[15]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[16]  C. Enders,et al.  Site‐independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumours , 2004, The Journal of pathology.

[17]  H. Joensuu.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[18]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[19]  Bernhard Kuster,et al.  Profiling Core Proteomes of Human Cell Lines by One-dimensional PAGE and Liquid Chromatography-Tandem Mass Spectrometry*S , 2003, Molecular & Cellular Proteomics.

[20]  H. Lee,et al.  Loss of promyelocytic leukemia protein in human gastric cancers. , 2007, Cancer letters.

[21]  Ping Chen,et al.  Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies. , 2012, Experimental and therapeutic medicine.

[22]  Yu-Ru Lee,et al.  The role of PML ubiquitination in human malignancies , 2012, Journal of Biomedical Science.

[23]  S. Hirohashi,et al.  Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics , 2007, Nature Protocols.

[24]  S. Hirota,et al.  Differential expression of connexin 43 in gastrointestinal stromal tumours of gastric and small intestinal origin , 2005, The Journal of pathology.

[25]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[26]  X. Le,et al.  Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. , 1997, Carcinogenesis.

[27]  S. Hirohashi,et al.  Distinct gene expression-defined classes of gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[29]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[30]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[31]  P. Salomoni,et al.  New insights into the role of PML in tumour suppression , 2008, Cell Research.

[32]  S. Hirohashi,et al.  Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics , 2008, Clinical Cancer Research.

[33]  S. Lowe,et al.  PML is induced by oncogenic ras and promotes premature senescence. , 2000, Genes & development.

[34]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.

[35]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[36]  S. Hirota,et al.  Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients , 2013, International Journal of Clinical Oncology.

[37]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[38]  N. Socci,et al.  Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.

[39]  G. Sauter,et al.  Patterns of gene amplification in gastrointestinal stromal tumors (GIST) , 2005, Laboratory Investigation.

[40]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[41]  A. Kentsis,et al.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA , 2001, The EMBO journal.

[42]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[43]  Florian Haller,et al.  Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors , 2005, Clinical Cancer Research.

[44]  A. Heydebreck,et al.  Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors , 2007, Modern Pathology.

[45]  Mohieddin Jafari,et al.  Comparison of in‐gel protein separation techniques commonly used for fractionation in mass spectrometry‐based proteomic profiling , 2012, Electrophoresis.

[46]  Rosa Bernardi,et al.  PML regulates p53 stability by sequestering Mdm2 to the nucleolus , 2004, Nature Cell Biology.

[47]  K. Do,et al.  Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy , 2006, Cancer.

[48]  M. Ladanyi,et al.  Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[50]  Ming-Tsang Wu,et al.  Hypoxia-inducible Factor-1α is Associated with Risk of Aggressive Behavior and Tumor Angiogenesis in Gastrointestinal Stromal Tumor , 2005 .

[51]  D.,et al.  Regression Models and Life-Tables , 2022 .